🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Ridinilazole

    Summit Therapeutics

    Clostridioides Difficile Infection

    phase 3 small molecule completed

    2 trials

  2. Rifampicin

    United Therapeutics Europe Ltd

    Severe Acute Malnutrition

    phase 3 small molecule active

    1 trial

  3. Rifaximin

    The First People's Hospital of Lianyungang

    Crohn Disease

    phase 3 small molecule active

    1 trial

  4. Riluzole

    United Therapeutics Europe Ltd

    Spinal Cord Injury

    phase 3 small molecule terminated

    1 trial

  5. Rilvegostomig, DS-8201a, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CARBOPLATIN, DOCETAXEL, PACLITAXEL

    AstraZeneca AB

    HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  6. Rilvegostomig, TEGAFUR, GLUCOSE, INFLIXIMAB, CAPECITABINE, CISPLATIN, MYCOPHENOLATE MOFETIL, TEGAFUR, CAPECITABINE, GEMCITABINE, SODIUM CHLORIDE

    AstraZeneca AB

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    phase 3 small molecule active

    1 trial

  7. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  8. Rituximab

    The First People's Hospital of Lianyungang

    Refractory Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  9. Rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    3 trials

  10. Rituximab

    United Therapeutics Europe Ltd

    Kidney Transplant Rejection

    phase 3 small molecule terminated

    1 trial

  11. Rituximab

    United Therapeutics Europe Ltd

    Follicular Lymphoma

    phase 3 small molecule completed

    1 trial

  12. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Venous Thromboembolism

    phase 3 small molecule completed

    2 trials

  13. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Pulmonary Embolism

    phase 3 small molecule completed

    1 trial

  14. Rivaroxaban (Xarelto, BAY59-7939)

    Bayer HealthCare AG

    Prevention & Control

    phase 3 small molecule completed

    1 trial

  15. Rivaroxaban 2.5 Mg Oral Tablet

    The George Institute

    Chronic Kidney Diseases

    phase 3 small molecule completed

    1 trial

  16. Rivastigmine Transdermal System

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 3 small molecule completed

    1 trial

  17. RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  18. Robotic Gastrectomy

    The First People's Hospital of Lianyungang

    Gastric Cancer (GC)

    phase 3 other active

    1 trial

  19. Roflumilast 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  20. Roflumilast Cream

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  21. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  22. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  23. Roflumilast Foam

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 3 small molecule completed

    1 trial

  24. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Scalp Psoriasis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources